Ophthotech Enrolls First Patient in a Phase I Complement (Anti-C5) Inhibitor Trial for Macular Degeneration
10/27/2008 9:57:34 AM
PRINCETON, NJ and NEW YORK, NY--(Marketwire - October 27, 2008) - Ophthotech Corp. ("Ophthotech"), a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, announced today the enrollment of its first patient in a complement inhibition trial for the treatment of age-related macular degeneration (AMD). This Phase I trial will assess the safety and tolerability of ARC1905, an anti-C5 complement factor aptamer, in combination with an anti-VEGF agent.
comments powered by